Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG -1.61%41 FCF Margin % is 1.57% as of Mar. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.45 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 79.31% on this metric.
The historical rank and industry rank for Interpace Biosciences's FCF Margin % or its related term are showing as below:
IDXG'
s FCF Margin % Range Over the Past 10 Years
Min: -96.19 Med: -34.53 Max: 14.14
Current: 13.07
During the past 13 years, the highest FCF Margin % of Interpace Biosciences was 14.14%. The lowest was -96.19%. And the median was -34.53%.
IDXG's FCF Margin % is ranked better than 79.31% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs IDXG: 13.07
Interpace Biosciences FCF Margin % Related Terms
Interpace Biosciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Interpace Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a FCF Margin % of 1.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #42 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 20.7%.
Is Interpace Biosciences' FCF Margin % too high?
Interpace Biosciences' current FCF Margin % is 1.57%. Based on the distribution chart, Interpace Biosciences ranks #42 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' FCF Margin % compare to PRPO and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #42 out of 203 companies for FCF Margin %. This places Interpace Biosciences in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current FCF Margin % is 1.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $1.53 — trading 238.9% above its estimated fair value. The current FCF Margin % is 1.57%. Interpace Biosciences' overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current FCF Margin % is 1.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.53 is trading 238.9% above its estimated GF Value™ of $0.45.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
FCF Margin %: 1.57%
GF Value™: $0.45 vs. price of $1.53 (238.9% above fair value)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
